Abstract 108P
Background
About 70% of patients with colorectal cancer develop liver metastases (LM). Although colorectal cancer patients with resectable LM have a good prognosis, there is little data at the difference in the locations of LM. We investigated how the location of LM affects prognosis of colorectal cancer patients.
Methods
The medical records of 196 colorectal cancer patients with liver metastasis from January 2008 to December 2018 were analyzed retrospectively. We defined liver metastasis within a 3-cm-radius sphere centered on the bifurcation of portal vein by computed tomography as central LM (group C), and other LM outside the 3-cm-radius sphere as peripheral LM (group P). We investigated the relation between location of LM and prognosis by using the Kaplan-Meier method and log-rank test, and the relation between location of LM and resection by using the chi-square test.
Results
Patient characteristics were as follows: median age 68.4 (range 30-87), female/male 115/81, colon/rectal cancer 117/79, advanced/recurrent 150/46, respectively. The characteristics of liver metastasis were as follows: mean maximum tumor size 38 mm (3 - 200), tumor number single/multi 58/138, group C/P 84/112, respectively. Median overall survival (OS) was 31 months [95% confidence interval (CI), 25.5 to 36.5 months] from the date of first diagnosis of LM. We divided 196 patients into two groups ofgroup C (n = 84) and group P (n = 112) by location of LM. Resection rate of LM was 11.9% (group C) and 50.9% (group P). Median OS in group C and group P was 18 months (95% CI, 12.3 to 23.7 months) and 38 months (95% CI, 35.2 to 40.8 months), respectively (p < 0.001). Resection of LM was performed significantly more often in group P than in group C (p < 0.001). Furthermore, the patients with resectable LM had a good prognosis not only in group P (mean OS 135 months, 95% CI, 109.4 to 160.7 months) but also in group C (mean OS 82 months, 95% CI, 67.5 to 96.0 months).
Conclusions
It is suggested that the colorectal cancer patients with peripheral LM might have a better prognosis than the patients with central LM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
528P - High-biologically effective dose radiotherapy may improve local control of small cell lung cancer patients with brain metastases: A propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster display session
Resources:
Abstract
530P - Prognostic value of C-reactive protein, albumin and C-reactive protein to albumin ratio in small cell lung cancer: A meta-analysis
Presenter: Carla Emille Barbon
Session: Poster display session
Resources:
Abstract
531TiP - CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC
Presenter: Byoung Chul Cho
Session: Poster display session
Resources:
Abstract
532TiP - CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC
Presenter: Daniel Shao Weng Tan
Session: Poster display session
Resources:
Abstract
533TiP - CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx)
Presenter: Darren Lim
Session: Poster display session
Resources:
Abstract
534TiP - A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for NSCLC with IPF (J-SONIC)
Presenter: Kohei Otsubo
Session: Poster display session
Resources:
Abstract
535TiP - Phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonia (TORG1936 / AMBITIOUS study)
Presenter: Satoshi Ikeda
Session: Poster display session
Resources:
Abstract
536TiP - INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
Presenter: James C-H Yang
Session: Poster display session
Resources:
Abstract
YO8 - Carcinosarcoma of the Breast in a Filipino Female: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO9 - Small Malignant Phyllodes Tumor of the Breast with Metastases to the Lung and Bone
Presenter: Gusti Harti
Session: Poster display session
Resources:
Abstract